Cost-effectiveness analysis of 10 Years Versus 5 Years of tamoxifen in Breast Cancer

  • Thanasitthichai S, Srisubat A, Thaiyakul A, Guayraksa K, Boonmark K
Keywords: Breast cancer, Tamoxifen, QALY

Downloads

Download data is not yet available.

References

Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJL, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378(9801):1461–84.

Deerasamee S, Martin N, Sontipong S, Vatanasapt C, Sriamporn S, Parkin D, et al. Cancer in Thailand, Vol. II, 1992-1994. Lyon: IARC Library Cataloguing in Publication Data; 1999.

Sriplung H, Sontipong S, Martin N, Wiangnon S, Vootiprux V, Cheirsilapa A, et al. Cancer in Thailand, Vol. III, 1995-1997. Bangkok: Bangkok Medical Publisher; 2004.

Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P, et al. Cancer in Thailand, Vol. IV, 1998-2000. Bangkok: Bangkok Medical Publisher; 2007.

Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P, et al. Cancer in Thailand, Vol. V, 2001-2003. Bangkok: Bangkok Medical Publisher; 2010.

Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P, et al. Cancer in Thailand, Vol. VI, 2004-2006. Bangkok: Bangkok Medical Publisher; 2012.

Khuhaprema T, Srivatanakul P, Sriplung H, Wiangnon S, Sumitsawan Y, Attasara P, et al. Cancer in Thailand, Vol. VII, 2007-2009. Bangkok: Bangkok Medical Publisher; 2013.

Imsamran W, Chaiwerawattana A, Wiangnon S, Pongnikorn D, Suwanrungruang K, Sangrajrang S, et al. Cancer in Thailand, Vol. VIII, 2010-2012. Bangkok: Bangkok Medical Publisher; 2015.

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383(9935):2127–35.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386(10001):1341–52.

Rossi S, Basso M, Strippoli A, Dadduzio V, Cerchiaro E, Barile R, et al. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared with Synchronous Axillary Metastases or Recurrent Metastatic Disease. Clin Breast Cancer 2015; 15:307–12.

Krøigård AB, Larsen MJ, Lænkholm A-V, Knoop AS, Jensen JD, Bak M, et al. Clonal expansion and linear genome evolution through breast cancer progression from preinvasive stages to asynchronous metastasis. Oncotarget 2015; 6:5634–49.

Semenza GL. The hypoxic tumor microenvironment: A driving force for breast cancer progression. Biochim Biophys Acta 2016; 1863:382–91.

Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988; 319:1681–92.

Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451–67.

Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381:805–16.

Gray R, Rea D, Handley K, Marshall A, Pritchard M, Perry P, et al. aTTom (adjuvant Tamoxifen—To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer—Preliminary results. J Clin Oncol. 2008; 26(15_suppl):513.

Gray R, Rea D, Handley K, Bowden S, Perry P, Earl H, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 2013; 31:5.

Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, et al. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996; 74:297–9.

Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93:684–90.

U.S. Food and Drug Administration: Tamoxifen 1998; (cited 2017, April 6): [Internet]. Available from: URL; https://www. fda.gov/NewsEvents/Testimony/ucm115118.htm.

Permsuwan U, Guntawongwan K, Buddhawongsa P. Handling time in economic evaluation studies. J Med Assoc Thai 2014; 97 Suppl 5: S50–8.

World Health Organization. Cost effectiveness and strategic planning (WHO-CHOICE). (cited 2016, July 30): [Internet]. Available from: https://www.who.int/choice/costs/en/.

Published
2019-06-01
How to Cite
1.
Thanasitthichai S, Srisubat A, Thaiyakul A, Guayraksa K, Boonmark K. Cost-effectiveness analysis of 10 Years Versus 5 Years of tamoxifen in Breast Cancer. j dept med ser [Internet]. 2019Jun.1 [cited 2021Oct.26];44(3):100-7. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/246800
Section
Original Article